Home > Cardiology > ACC/WCC 2020 > Vascular Medicine and Thromboembolism > TAILOR-PCI misses endpoint but still provides valuable insights

TAILOR-PCI misses endpoint but still provides valuable insights

Presented By
Prof. N. Pereira, Mayo Clinic, USA
ACC 2020
Although it missed its primary endpoint of a 50% reduction in cardiovascular (CV) events at 1 year, the TAILOR-PCI trial demonstrated a 34% reduction in CV events, alongside a statistically significant 40% reduction in the total number of events per patient receiving genetically-guided treatment versus patients receiving standard treatment [1]. TAILOR-PCI, presented by Prof. Naveen Pereira (Mayo Clinic, USA), is the largest trial to date to investigate the clinical utility of using genetic testing to detect the clopidogrel loss-of-function (LOF) genotype to guide antiplatelet therapy in patients undergoing percutaneous coronary intervention (PCI). The trial enrolled 5,302 patients who had had PCI with stenting. Patients received standard antiplatelet therapy with clopidogrel 75 mg/day without genetic testing or antiplate...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on